Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Hooftman

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Nature|January 20, 2022
Nanoparticle asymmetry shapes an immune responseAlexander Hooftman, Luke A J O'Neill
Cell|June 25, 2026
The cGAS-STING pathway: Mechanism and medical implicationsAlexander Hooftman, Alexander Keller, Andrea Ablasser
Current Research in Pharmacology and Drug Discovery|December 6, 2021
Can NLRP3 inhibitors improve on dexamethasone for the treatment of COVID-19?Alexander Hooftman, Luke A J O'Neill
Trends in Immunology|June 11, 2019
The Immunomodulatory Potential of the Metabolite ItaconateAlexander Hooftman, Luke A J O'Neill
Nature Cell Biology|July 9, 2021
SARS-CoV-2 targets MAVS for immune evasionAlessia Zotta, Alexander Hooftman, Luke A J O'Neill
Clinical and Translational Medicine|September 6, 2023
Inflammatory mitochondrial nucleic acids as drivers of pathophysiologyChristian G Peace, Alexander Hooftman, Dylan G Ryan
Journal of Innate Immunity|November 23, 2023
Basic Mechanisms of Immunometabolites in Shaping the Immune ResponseDylan Gerard Ryan, Christian Graham Peace, Alexander Hooftman
Cell Metabolism|August 14, 2020
The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome ActivationAlexander Hooftman, Stefano Angiari, Svenja Hester, et al.
Biochemical Pharmacology|April 27, 2026
4-Octyl itaconate blocks STAT3-induced ACE2 expression to reduce uptake of SARS-CoV-2Hauke J Weiss, Alexander Hooftman, Clarisse Salgado-Benvindo, et al.
Nature Metabolism|December 12, 2024
Author Correction: Itaconate drives mtRNA-mediated type I interferon production through inhibition of succinate dehydrogenaseShane M O'Carroll, Christian G Peace, Juliana E Toller-Kawahisa, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Nature|January 20, 2022
Nanoparticle asymmetry shapes an immune responseAlexander Hooftman, Luke A J O'Neill
Cell|June 25, 2026
The cGAS-STING pathway: Mechanism and medical implicationsAlexander Hooftman, Alexander Keller, Andrea Ablasser
Current Research in Pharmacology and Drug Discovery|December 6, 2021
Can NLRP3 inhibitors improve on dexamethasone for the treatment of COVID-19?Alexander Hooftman, Luke A J O'Neill
Trends in Immunology|June 11, 2019
The Immunomodulatory Potential of the Metabolite ItaconateAlexander Hooftman, Luke A J O'Neill
Nature Cell Biology|July 9, 2021
SARS-CoV-2 targets MAVS for immune evasionAlessia Zotta, Alexander Hooftman, Luke A J O'Neill
Clinical and Translational Medicine|September 6, 2023
Inflammatory mitochondrial nucleic acids as drivers of pathophysiologyChristian G Peace, Alexander Hooftman, Dylan G Ryan
Journal of Innate Immunity|November 23, 2023
Basic Mechanisms of Immunometabolites in Shaping the Immune ResponseDylan Gerard Ryan, Christian Graham Peace, Alexander Hooftman
Cell Metabolism|August 14, 2020
The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome ActivationAlexander Hooftman, Stefano Angiari, Svenja Hester, et al.
Biochemical Pharmacology|April 27, 2026
4-Octyl itaconate blocks STAT3-induced ACE2 expression to reduce uptake of SARS-CoV-2Hauke J Weiss, Alexander Hooftman, Clarisse Salgado-Benvindo, et al.
Nature Metabolism|December 12, 2024
Author Correction: Itaconate drives mtRNA-mediated type I interferon production through inhibition of succinate dehydrogenaseShane M O'Carroll, Christian G Peace, Juliana E Toller-Kawahisa, et al.
Pageof 2